1. Home
  2. SHCO vs MLYS Comparison

SHCO vs MLYS Comparison

Compare SHCO & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SHCO
  • MLYS
  • Stock Information
  • Founded
  • SHCO 1995
  • MLYS 2019
  • Country
  • SHCO United Kingdom
  • MLYS United States
  • Employees
  • SHCO N/A
  • MLYS N/A
  • Industry
  • SHCO Hotels/Resorts
  • MLYS Biotechnology: Pharmaceutical Preparations
  • Sector
  • SHCO Consumer Discretionary
  • MLYS Health Care
  • Exchange
  • SHCO Nasdaq
  • MLYS Nasdaq
  • Market Cap
  • SHCO 1.0B
  • MLYS 890.6M
  • IPO Year
  • SHCO 2021
  • MLYS 2023
  • Fundamental
  • Price
  • SHCO $8.85
  • MLYS $37.01
  • Analyst Decision
  • SHCO Strong Buy
  • MLYS Strong Buy
  • Analyst Count
  • SHCO 1
  • MLYS 6
  • Target Price
  • SHCO $9.00
  • MLYS $42.60
  • AVG Volume (30 Days)
  • SHCO 2.4M
  • MLYS 2.6M
  • Earning Date
  • SHCO 08-08-2025
  • MLYS 11-10-2025
  • Dividend Yield
  • SHCO N/A
  • MLYS N/A
  • EPS Growth
  • SHCO N/A
  • MLYS N/A
  • EPS
  • SHCO N/A
  • MLYS N/A
  • Revenue
  • SHCO $1,251,591,000.00
  • MLYS N/A
  • Revenue This Year
  • SHCO $10.81
  • MLYS N/A
  • Revenue Next Year
  • SHCO $7.12
  • MLYS N/A
  • P/E Ratio
  • SHCO N/A
  • MLYS N/A
  • Revenue Growth
  • SHCO 9.00
  • MLYS N/A
  • 52 Week Low
  • SHCO $4.60
  • MLYS $8.24
  • 52 Week High
  • SHCO $8.92
  • MLYS $39.20
  • Technical
  • Relative Strength Index (RSI)
  • SHCO 75.30
  • MLYS 85.99
  • Support Level
  • SHCO $8.81
  • MLYS $35.00
  • Resistance Level
  • SHCO $8.88
  • MLYS $39.20
  • Average True Range (ATR)
  • SHCO 0.03
  • MLYS 2.55
  • MACD
  • SHCO -0.06
  • MLYS 1.70
  • Stochastic Oscillator
  • SHCO 50.00
  • MLYS 91.00

About SHCO Soho House & Co Inc.

Soho House & Co Inc is a membership platform of physical and digital spaces that connects a vibrant, diverse group of members from across the world. The members use the platform to work, socialize, connect, create, and flourish all over the world. It offers lease agreements for Houses, hotels, restaurants, studios, spas, and other properties. The company's reportable segments are: United Kingdom; The Americas; and Europe and Rest of the world. The majority of its revenue is generated from the Americas segment, which encompasses its operating units in the Americas, including Soho Houses, stand-alone U.S. restaurants, Soho Friends, and the management fees under a hotel management contract for the operation of The Ned London.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

Share on Social Networks: